FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1022-1023 March 29, 2001 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: Mandel and associates (Nov. 30 issue)¹ show that either annual or biennial fecal occult-blood testing significantly reduces the incidence of colorectal cancer. Their findings were primarily the result of using the equivalent of the rehydrated Hemoccult II card, a fecal occult-blood test that has good sensitivity but poor specificity and that is not currently recommended for use by its manufacturer (Beckman Coulter, Fullerton, Calif.). Thus, the results with the rehydrated Hemoccult II card cannot be used to support its use in routine clinical practice.

The nonrehydrated Hemoccult II is the most widely used fecal occult-blood test in . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.